File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18f-Fdg Pet/Ct) in staging breast cancers of different clinical stages and subtypes

TitleThe role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18f-Fdg Pet/Ct) in staging breast cancers of different clinical stages and subtypes
Authors
Issue Date2021
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1744-1633
Citation
The Royal College of Surgeons of Edinburgh and The College of Surgeons of Hong Kong (RCSEd/CSHK) Conjoint Virtual Scientific Congress 2021: Emerging Technology for Surgery, Hong Kong, 11-12 September 2021. In Surgical Practice, 2021, v. 25 n. Suppl. 1, p. 7, abstract no. FP9 How to Cite?
AbstractAim: Positron Emission Tomography with Computed Tomography (PET/CT) technology has the ability to detect clinically unsuspected nodal or distant metastases, but international guidelines discourage the use of PET/CT in localized breast cancers of stage IIIA or below. Our study aimed to evaluate the role of PET/CT in staging both early and locally advanced breast cancers. Method: We retrospectively studied 622 consecutive breast cancer patients who presented at clinical stages I–III and underwent pre-treatment PET/CT. Each patient's clinical staging was compared with the corresponding PET/CT results to assess the rates of distant metastasis and disease upstaging. Results: The detection rate of distant metastasis by PET/CT for clinical stages I, II and III were 0.7%, 6.7% and 27.5% respectively. Distant metastasis was identified most frequently in clinically localized breast cancers of the HER2-enriched subtype (11.8%), followed by luminal B (11.7%), basal (6.0%), and luminal A subtypes (5.6%). The upstaging rates for clinical stages I, II and III by PET-CT were 30.1%, 30.0% and 34.9% respectively. Basal breast cancer subtype showed the highest upstaging rate (38.8%), followed by HER2-enriched (37.7%), luminal B (34.8%), and luminal A subtypes (20.6%). Conclusion: PET/CT technology is effective in detecting distant metastasis particularly in clinical stage III, HER2-enriched and luminal B breast cancers. In addition, PET/CT leads to high rates of disease upstaging in all clinical stages and breast cancer subtypes. Our results suggest that more judicial use of PET/CT for more accurate staging of clinically localized breast cancers may be warranted to improve patient outcomes.
DescriptionOral Presentation - Free Paper - no. FP9
Persistent Identifierhttp://hdl.handle.net/10722/305100
ISSN
2023 Impact Factor: 0.3
2023 SCImago Journal Rankings: 0.152

 

DC FieldValueLanguage
dc.contributor.authorYu, SWY-
dc.contributor.authorMa, KK-
dc.contributor.authorYeung, MHY-
dc.contributor.authorChow, CYL-
dc.contributor.authorTsang, SJ-
dc.contributor.authorHo, LH-
dc.contributor.authorKwong, A-
dc.date.accessioned2021-10-05T02:39:43Z-
dc.date.available2021-10-05T02:39:43Z-
dc.date.issued2021-
dc.identifier.citationThe Royal College of Surgeons of Edinburgh and The College of Surgeons of Hong Kong (RCSEd/CSHK) Conjoint Virtual Scientific Congress 2021: Emerging Technology for Surgery, Hong Kong, 11-12 September 2021. In Surgical Practice, 2021, v. 25 n. Suppl. 1, p. 7, abstract no. FP9-
dc.identifier.issn1744-1625-
dc.identifier.urihttp://hdl.handle.net/10722/305100-
dc.descriptionOral Presentation - Free Paper - no. FP9-
dc.description.abstractAim: Positron Emission Tomography with Computed Tomography (PET/CT) technology has the ability to detect clinically unsuspected nodal or distant metastases, but international guidelines discourage the use of PET/CT in localized breast cancers of stage IIIA or below. Our study aimed to evaluate the role of PET/CT in staging both early and locally advanced breast cancers. Method: We retrospectively studied 622 consecutive breast cancer patients who presented at clinical stages I–III and underwent pre-treatment PET/CT. Each patient's clinical staging was compared with the corresponding PET/CT results to assess the rates of distant metastasis and disease upstaging. Results: The detection rate of distant metastasis by PET/CT for clinical stages I, II and III were 0.7%, 6.7% and 27.5% respectively. Distant metastasis was identified most frequently in clinically localized breast cancers of the HER2-enriched subtype (11.8%), followed by luminal B (11.7%), basal (6.0%), and luminal A subtypes (5.6%). The upstaging rates for clinical stages I, II and III by PET-CT were 30.1%, 30.0% and 34.9% respectively. Basal breast cancer subtype showed the highest upstaging rate (38.8%), followed by HER2-enriched (37.7%), luminal B (34.8%), and luminal A subtypes (20.6%). Conclusion: PET/CT technology is effective in detecting distant metastasis particularly in clinical stage III, HER2-enriched and luminal B breast cancers. In addition, PET/CT leads to high rates of disease upstaging in all clinical stages and breast cancer subtypes. Our results suggest that more judicial use of PET/CT for more accurate staging of clinically localized breast cancers may be warranted to improve patient outcomes.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1744-1633-
dc.relation.ispartofSurgical Practice-
dc.relation.ispartofThe Royal College of Surgeons of Edinburgh & The College of Surgeons of Hong Kong (RCSEd/CSHK ) Conjoint Scientific Congress 2021-
dc.titleThe role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18f-Fdg Pet/Ct) in staging breast cancers of different clinical stages and subtypes-
dc.typeConference_Paper-
dc.identifier.emailChow, CYL: lcychow@hku.hk-
dc.identifier.emailTsang, SJ: julianst@hku.hk-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.authorityKwong, A=rp01734-
dc.description.natureabstract-
dc.identifier.hkuros326104-
dc.identifier.volume25-
dc.identifier.issueSuppl. 1-
dc.identifier.spage7, abstract no. FP9-
dc.identifier.epage7, abstract no. FP9-
dc.publisher.placeAustralia-
dc.identifier.partofdoi10.1111/1744-1633.12518-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats